Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, 100044, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.
Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, 100044, People's Republic of China.
Cancer Lett. 2021 Mar 1;500:1-10. doi: 10.1016/j.canlet.2020.12.024. Epub 2020 Dec 23.
Osteosarcoma (OS) is the most common primary malignancy of the bone and has a high propensity for local invasion and metastasis. Although combining surgery with chemotherapy has immensely improved the outcomes of osteosarcoma patients, the prognosis of metastatic or recurrent osteosarcomas is still unsatisfactory. Immunotherapy has proven to be a promising therapeutic strategy against human malignancies and improved understanding of the immune response to OS, and biomarker development has increased the number of patients who benefit from immunotherapies in recent years. Here, we review recent advances in immunotherapy in osteosarcoma and discuss the mechanisms and status of immunotherapies in both preclinical and clinical trials as well as future therapies on the horizon. These advances may pave the way for novel treatments requisite for patients with osteosarcoma in need of new therapies.
骨肉瘤（OS）是最常见的原发性骨恶性肿瘤，具有很高的局部侵袭和转移倾向。尽管将手术与化疗相结合极大地改善了骨肉瘤患者的预后，但转移性或复发性骨肉瘤的预后仍然不理想。免疫疗法已被证明是一种对抗人类恶性肿瘤的有前途的治疗策略，并且对骨肉瘤免疫反应的理解以及生物标志物的开发近年来增加了受益于免疫疗法的患者数量。在这里，我们回顾了骨肉瘤免疫治疗的最新进展，并讨论了临床前和临床试验中免疫治疗的机制和现状，以及未来的治疗前景。这些进展可能为需要新疗法的骨肉瘤患者开辟新的治疗途径。
